Viral vector vaccines protect cockatiels from inflammatory lesions after heterologous parrot bornavirus 2 challenge infection

Runge, Solveig; Olbert, Marita; Herden, Christiane; Malberg, Sara; Römer-Oberdörfer, Angela; Staeheli, Peter; Rubbenstroth, Dennis

doi:10.1016/j.vaccine.2016.12.022

Cited by 23 publications

(44 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ey speculated that this would limit the commercial use of this vaccination protocol, although modifying the dose or immunization schedule could yield more desirable results. On the contrary, Runge and colleagues (2016) described experiments with cockatiels and canaries using live viral vector vaccines carrying the N and P genes of avian bornaviruses and a heterologous prime-boost vaccination regime that yielded positive tests for antibodies reactive to the virus [57]. However, the progress of the disease was delayed in these birds, not prevented, following exposure to a high viral challenge dose of avian bornaviruses [57].…”

Section: Vaccinationmentioning

confidence: 99%

“…On the contrary, Runge and colleagues (2016) described experiments with cockatiels and canaries using live viral vector vaccines carrying the N and P genes of avian bornaviruses and a heterologous prime-boost vaccination regime that yielded positive tests for antibodies reactive to the virus [57]. However, the progress of the disease was delayed in these birds, not prevented, following exposure to a high viral challenge dose of avian bornaviruses [57]. ey pointed out that, without fuller knowledge regarding the transmission of avian bornaviruses, it is difficult to identify the appropriate routes and viral dosages to use when testing new vaccines [57].…”

Section: Vaccinationmentioning

confidence: 99%

“…However, the progress of the disease was delayed in these birds, not prevented, following exposure to a high viral challenge dose of avian bornaviruses [57]. ey pointed out that, without fuller knowledge regarding the transmission of avian bornaviruses, it is difficult to identify the appropriate routes and viral dosages to use when testing new vaccines [57]. ese researchers speculated that naturally occurring infections of the disease may involve lower challenge dosages.…”

Section: Vaccinationmentioning

confidence: 99%

“…ese researchers speculated that naturally occurring infections of the disease may involve lower challenge dosages. ey therefore conducted additional experiments using 10-fold lower dosages of challenge infections and second booster vaccinations which appeared to be successful in protecting these birds against viral infection with reduced clinical signs, fewer gross lesions, and only one bird showing mononuclear infiltrations while also lowering viral loads in these birds [57].…”

Section: Vaccinationmentioning

confidence: 99%

See 3 more Smart Citations

Avian Bornaviral Ganglioneuritis: Current Debates and Unanswered Questions

Boatright-Horowitz

2020

Veterinary Medicine International

View full text Add to dashboard Cite

Avian bornaviral ganglioneuritis, often referred to as parrot wasting disease, is associated with a newly discovered avian virus from the taxonomic family Bornaviridae. Research regarding the pathogenesis and treatment for this disease is ongoing, with implications for understanding other emerging human and nonhuman diseases, as well as the health and ecology of wildlife. At this time, numerous questions remain unanswered regarding the transmission of the disease, best practices for diagnostic sampling and testing, and whether currently used drug therapies are effective or harmful for afflicted birds. The pathogenesis of the disease also remains unclear with many birds showing resistance to the effects of the virus and being able to remain clinically unaffected for years, while other birds succumb to its effects. New research findings regarding avian bornaviral ganglioneuritis are discussed and important as yet unanswered questions are identified.

show abstract

Section: Vaccinationmentioning

confidence: 99%

Section: Vaccinationmentioning

confidence: 99%

Section: Vaccinationmentioning

confidence: 99%

Section: Vaccinationmentioning

confidence: 99%

See 2 more Smart Citations

Avian Bornaviral Ganglioneuritis: Current Debates and Unanswered Questions

Boatright-Horowitz

2020

Veterinary Medicine International

View full text Add to dashboard Cite

show abstract

“…In some individuals, a PaBV infection causes proventricular dilatation disease (PDD), a peracute to chronic, often fatal disease usually associated with neurological and/or intestinal symptoms. In contrast, other persistently infected psittacines show no clinical symptoms for up to several years [5][6][7][8][9][10]. Immunopathogenesis is assumed to be required for the development of PDD, providing a possible explanation for this pattern [6].…”

Section: Introductionmentioning

confidence: 99%

Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines Efficiently Protect Cockatiels Against Parrot Bornavirus Infection and Proventricular Dilatation Disease

Rall

Amann

Malberg

et al. 2019

Viruses

Self Cite

View full text Add to dashboard Cite

Parrot bornaviruses (PaBVs) are the causative agents of proventricular dilatation disease (PDD), a chronic and often fatal neurologic disorder in Psittaciformes. The disease is widely distributed in private parrot collections and threatens breeding populations of endangered species. Thus, immunoprophylaxis strategies are urgently needed. In previous studies we demonstrated a prime-boost vaccination regime using modified vaccinia virus Ankara (MVA) and Newcastle disease virus (NDV) constructs expressing the nucleoprotein and phosphoprotein of PaBV-4 (MVA/PaBV-4 and NDV/PaBV-4, respectively) to protect cockatiels (Nymphicus hollandicus) against experimental challenge infection. Here we investigated the protective effect provided by repeated immunization with either MVA/PaBV-4, NDV/PaBV-4 or Orf virus constructs (ORFV/PaBV-4) individually. While MVA/PaBV-4-vaccinated cockatiels were completely protected against subsequent PaBV-2 challenge infection and PDD-associated lesions, the course of the challenge infection in NDV/PaBV-4- or ORFV/PaBV-4-vaccinated birds did not differ from the unvaccinated control group. We further investigated the effect of vaccination on persistently PaBV-4-infected cockatiels. Remarkably, subsequent immunization with MVA/PaBV-4 and NDV/PaBV-4 neither induced obvious immunopathogenesis exacerbating the disease nor reduced viral loads in the infected birds. In summary, we demonstrated that vaccination with MVA/PaBV-4 alone is sufficient to efficiently prevent PaBV-2 challenge infection in cockatiels, providing a suitable vaccine candidate against avian bornavirus infection and bornavirus-induced PDD.

show abstract